Chat with us, powered by LiveChat Innovate | Lhasa Limited

Innovate

Discover the latest innovations in computer-aided reasoning and information systems.

Our latest blog uncovers how to meet ICH Q3D guidelines with ease using our new tool Vitic Q3D.

Avoid unnecessary testing: Achieve confident ICH Q3D compliance using regulatory aligned consortium data

Approaching regulatory compliance with confidence ICH Q3D guidelines require assessing and controlling elemental impurities for regulatory compliant development of drug products. The workflow emphasises a risk-based control strategy to limit elemental impurities, which can be derived from residual catalysts, raw materials, reagents that can be present in the API or excipient of the drug product. […]

Avoid unnecessary testing: Achieve confident ICH Q3D compliance using regulatory aligned consortium data Read More »

Lhasa Limited shortlisted for the Lush Prize 2026 for science, advancing non-animal approaches to DART through human-relevant, in silico toxicology.

We’ve been shortlisted for the Lush Prize 2026 – Science

We’re delighted to share that Lhasa Limited has been shortlisted for the Lush Prize 2026 in the Science category, an award recognising research teams whose work is most likely to lead to practical, regulator-accepted non-animal testing approaches. The Lush Prize exists to accelerate the transition to 21st-century toxicology, with the ultimate goal of ending the

We’ve been shortlisted for the Lush Prize 2026 – Science Read More »

Untitled design 15

5 key takeaways from the Lhasa/IPEC Nitrites in Excipients collaborative meeting

We recently had the pleasure of hosting the second Lhasa/IPEC Nitrites in Excipients Collaborative Meeting at our Head Office in Leeds. Following on from the success of last year, this day served as a vital, in-person platform to bring together members from the Lhasa Nitrites data sharing consortium, IPEC Europe – European Excipients Association, excipient

5 key takeaways from the Lhasa/IPEC Nitrites in Excipients collaborative meeting Read More »

Lhasa attended - E&Ls Europe 2025: Building defensible justifications under ICH Q3E

E&Ls Europe 2025: Building defensible justifications under ICH Q3E

Insights on ICH Q3E, Extractables & Leachable (E&L) and risk assessment submissions Interpreting grey areas in the draft ICH Q3E guideline Earlier this month, the Lhasa Limited team, alongside Dr Lance Molnar, Head of Non-Clinical Operations and Risk Assessments at Viatris, and Dr Patricia Parris, Toxicology Impurity Risk Management at Pfizer, attended the Smithers E&L

E&Ls Europe 2025: Building defensible justifications under ICH Q3E Read More »

ICH S1B(R1) live Q&A webinar

Insights from the experts: Key takeaways from the ICH S1B(R1) live Q&A

Following our recent Lhasa Limited hosted webinar, ICH S1B(R1): industry and regulatory best practice for confident carcinogenicity assessment, attendees had the rare opportunity to engage directly with experts who helped shape the ICH S1B(R1) Addendum. The ICH S1B(R1) Addendum is a globally recognised guideline that introduces a weight-of-evidence (WoE) approach to assessing the carcinogenic potential

Insights from the experts: Key takeaways from the ICH S1B(R1) live Q&A Read More »

Discover how Vitic can assist with providing expert toxicity data for the ICH M7 guidelines on mutagenic impurities for an efficient workflow.

Driving efficient early-stage ICH M7 classification through reliable mutagenic and carcinogenic data

In this latest blog, we will define the difference between certainty and uncertainty in the ICH M7 guideline for mutagenic impurities. Delving into the power of existing experimental data, we’ll address how Vitic’s expert toxicity database can accelerate the workflow of Classes 1, 2 and 5 in mutagenicity risk assessments. To Toxicologists, the ICH M7

Driving efficient early-stage ICH M7 classification through reliable mutagenic and carcinogenic data Read More »

KAptis Weight of Evidence ICH S1b(r1)

Applying ICH S1B(R1) in 5 steps: Carcinogenicity assessment made simple with Kaptis

Carcinogenicity assessment is a critical step in drug development. Teams must balance regulatory compliance, development timelines, and ethical testing, often with incomplete datasets. The revised ICH S1B(R1) guideline introduces a weight-of-evidence (WoE) approach that provides a more structured, efficient, and human-relevant path forward. By applying this framework, organisations can benefit from: $2 – 4M cost

Applying ICH S1B(R1) in 5 steps: Carcinogenicity assessment made simple with Kaptis Read More »

blog images

ICH M7 control option 4: How to confidently demonstrate control of mutagenic impurities in API synthesis (without analytical testing)

If you’re currently relying solely on analytical testing to check for mutagenic impurities in your active pharmaceutical ingredient (API), there is a more time- and cost-effective option available that doesn’t compromise patient safety. Recent data for a medium-sized pharmaceutical company showed that you could save $1.35M annually and reduce time taken by 77%, using in

ICH M7 control option 4: How to confidently demonstrate control of mutagenic impurities in API synthesis (without analytical testing) Read More »

Ready to discover the power of in silico chemical structure search using Vitic? Here's everything you need to know about toxicity database searching

The power of in silico structure searching to achieve data driven decision making with confidence

In this blog, we explore the value of chemical structure search functionality in Vitic. Structure searching directs our members toward toxicity insights that can help guide their risk and safety assessments. We’ll discuss how chemical structure searches are conducted and the value that a toxicity database like Vitic can bring to decision making. A key

The power of in silico structure searching to achieve data driven decision making with confidence Read More »

The evolving role of genotox assessments

Webinar recap: Industry and regulator perspectives on in silico genotoxicity assessment

In a recent Lhasa Limited webinar, experts from BfR (the German Federal Institute for Risk Assessment), Syngenta, and Lhasa came together to explore how in silico tools are being used to support genotoxicity assessments. The session delivered a thorough overview of how these advanced computational methods are applied in both regulatory and industry settings, focusing

Webinar recap: Industry and regulator perspectives on in silico genotoxicity assessment Read More »